Dongsung Pharmaceutical동성제약
002210 · KOSPI · ₩002210 · 동성제약
- Market cap
- ₩120B
- Enterprise value
- ₩121B
- P/E
- —
- P/B
- 1.4×
- Dividend yield
- 0.0%
- ROE
- −14.7%
- Net margin
- −15.6%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−50.9% from the high
₩1,161Today: ₩1,211 – ₩1,259₩2,525
Returns
- 1W−5.1%
- 1M−2.0%
- 3M−36.3%
- 6M−36.3%
- YTD−36.3%
- 1Y−36.3%
- Volume today
- 37,046
- 0.8× the 20-day average
- Traded today
- ₩45M
- Listed shares
- 96,619,507
- EPS (12 months)
- −₩133
- Earnings yield −10.7%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 39 of 100 (50 is a normal day for this stock).
- MomentumFlat-4% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Dongsung Pharmaceutical stock overview
Dongsung Pharmaceutical (동성제약, KRX: 002210) is listed on KOSPI, in the Biotech & Pharma sector. The company is headquartered in Dobong-gu, Seoul, and operates a production plant and central research institute in Asan, Chungnam, along with a research lab in Seocho-gu, Seoul, and a cancer center in Daegu, with 13 business sites in total. Its shares closed at ₩1,240 on Oct 27, 2026, up 1.56% on the day, giving it a market value of ₩120B.
Key facts
- Market cap
- ₩120B
- Sector
- Biotech & Pharma
- Latest price change
- +1.56%
- As of
- Oct 27, 2026
- Main business
- The company is headquartered in Dobong-gu, Seoul, and operates a production plant and central research institute in Asan, Chungnam, along with a research lab in Seocho-gu, Seoul, and a cancer center in Daegu, with 13 business sites in total.
Quick answers about Dongsung Pharmaceutical
- What does Dongsung Pharmaceutical do?
- The company is headquartered in Dobong-gu, Seoul, and operates a production plant and central research institute in Asan, Chungnam, along with a research lab in Seocho-gu, Seoul, and a cancer center in Daegu, with 13 business sites in total. CARE in cosmetics. Most pharmaceutical and hair dye products are manufactured at its Asan plant, while other product lines are purchased and resold, and sales are made to hospitals, pharmacies, wholesalers, and overseas agencies in Korea and abroad.
- What is the market cap of Dongsung Pharmaceutical?
- The market capitalisation of Dongsung Pharmaceutical was ₩120B at the close on Oct 27, 2026.
- Who are the largest shareholders of Dongsung Pharmaceutical?
- According to the latest official filings, the largest reported holders are Yuanko Pharmaceutical Industry 1st Corporate Financial Stability Private Equity Fund (81.98%, as of Apr 15, 2026); Taekwang Industrial (37.60%, as of Apr 15, 2026); Lee Yang-gu (21.26%, as of Apr 1, 2025).
- When is the next earnings report from Dongsung Pharmaceutical?
- Korean companies rarely announce results dates in advance. Based on when Dongsung Pharmaceutical filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Dongsung Pharmaceutical?
- Yes. The National Pension Service held 0.00% of Dongsung Pharmaceutical shares as of Dec 31, 2025.
Company profile
The company is headquartered in Dobong-gu, Seoul, and operates a production plant and central research institute in Asan, Chungnam, along with a research lab in Seocho-gu, Seoul, and a cancer center in Daegu, with 13 business sites in total. It runs three business segments, pharmaceuticals, hair dyes and cosmetics, with main products including Jeongrohwan, Dongsung Minoxidil and Roxo&Gel in pharmaceuticals, Seven8 and EZN in hair dyes, and Lanze and AC.CARE in cosmetics. Most pharmaceutical and hair dye products are manufactured at its Asan plant, while other product lines are purchased and resold, and sales are made to hospitals, pharmacies, wholesalers, and overseas agencies in Korea and abroad.
Written by AI from the company's latest annual report.
- Korean name
- 동성제약
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- Business group
- Taekwang Industrial
- CEO
- 최용석
- Founded
- Nov 1957
- Listed
- Jan 1990
- Listed shares
- 96,619,507
- Fiscal year ends
- Month 12
- Website
- dongsung-pharm.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Lawsuit filed or ruledSep 30, 2026
- Lawsuit filed or ruledSep 14, 2026
- Disclosure on Large Business Group Status [Quarterly Disclosure (For Individual Company)]Aug 27, 2026
- Amended: Half-year report (Jun 2026)Aug 18, 2026
- Half-year report (Jun 2026)Aug 14, 2026
Titles in Korean until English translations are added.
Also known as: Dongsung Pharmaceutical / 동성제약 / 002210 / KRX:002210
Source: KRX statistical information